| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Nature communications 6 (1), 6169, 2015 | 329 | 2015 |
| Nanoengineered disruption of heat shock protein 90 targets drug-induced resistance and relieves natural killer cell suppression in breast cancer M Smalley, SK Natarajan, J Mondal, D Best, D Goldman, B Shanthappa, ... Cancer research 80 (23), 5355-5366, 2020 | 14 | 2020 |
| Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015; 6: 6169 B Majumder, U Baraneedharan, S Thiyagarajan, P Radhakrishnan, ... Epub 2015/02/28. https://doi. org/10.1038/ncomms7169 PMID: 25721094, 0 | 6 | |
| Integrating systems biology and an ex vivo human tumor model elucidates PD-1 blockade response dynamics M Smalley, M Przedborski, S Thiyagarajan, M Pellowe, A Verma, ... Iscience 23 (6), 2020 | 5 | 2020 |
| Predicting tumor-immune response to checkpoint inhibitors using a novel patient-derived live tumor explant model. P Radhakrishnan, A Goldman, B Ulaganathan, A Thaya Kumar, ... Journal of Clinical Oncology 35 (15_suppl), e20035-e20035, 2017 | 4 | 2017 |
| Nonuniform T-cell infiltration induced by PD-1 checkpoint blockade, ex vivo, predicts distinct clinical response M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Cancer Research 78 (13_Supplement), 705-705, 2018 | 1 | 2018 |
| Abstract LB-346: Case study: Non-uniform response to therapy in multiple metastatic is predicted using CANscriptTM, a live tissue, ex-vivo, platform C Ikpeazu, M Smalley, B Ulaganathan, A Thayakumar, L Majeiko, ... Cancer Research 78 (13_Supplement), LB-346-LB-346, 2018 | 1 | 2018 |
| Profiling metastatic lesions from a pembro-refractory patient to reveal distinct genomic instabilities and non-uniform response to drug combinations, ex vivo. C Ikpeazu, M Smalley, B Ulaganathan, A Thayakumar, S Basavaraja, ... Journal of Clinical Oncology 36 (15_suppl), e18021-e18021, 2018 | 1 | 2018 |
| A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo M Smalleye, N Alam, N Murmu, SP Somashekhar, B Ulaganathan, ... SABCS, 2018 | 1 | 2018 |
| Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Annals of Oncology 28, xi9, 2017 | 1 | 2017 |
| Characterizing immunotherapy-induced lymphocyte infiltration at the single patient level using CANscriptTM, an ex-vivo human tumor model M Smalleyc, BU Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... Immunotherapy of cancer 5, 2017 | 1 | 2017 |
| Identification of responders for Anti-CTLA4 in refractory colorectal cancers using CANScript™ platform B Majumder, B Ulaganathan, A Thayakumar, S Thiyagarajan, N Brijwani, ... Cancer Research 75 (15_Supplement), 1304-1304, 2015 | 1 | 2015 |
| 143 Correlating RNA-seq detection and IHC staining of potential antibody-drug conjugate (ADC) targets: HER3, HER2, TROP2, Nectin4, and aFLR V Kushnarev, D Stupichev, K Kryukov, S Davitavyan, M Johnson, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Interrogating the effect of oncolytic Herpes simplex virus-1 on spatial arrangement of myeloid cells in glioblastoma multiforme using an ex vivo human system and multiplex … M Smalley, M Jain, S Thyiagarajan, E Alonzo, K Crosby, D Best, H Gertje, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| An ex-vivo human system elucidates a role for natural killer cells in the anticancer effect of drug combinations in triple negative breast cancer A Goldman, D Best, S Thiyagarajan, M Jain, B Shanthappa, M Smalley, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| Abstract P6-07-03: A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo M Smalley, N Alam, N Murmu, S Somashekhar, B Ulaganathan, ... Cancer Research 79 (4_Supplement), P6-07-03-P6-07-03, 2019 | | 2019 |
| Profiling PD-1 blockade pharmacodynamics using a live tissue explant model of head and neck squamous cell carcinoma AG Munisha Smalley, PharmD, Steven B. Maron, MD, Manjusha Biswas, MD, Mark ... Journal for ImmunoTherapy of Cancer 6, 2018 | | 2018 |
| Clinical-stage monitoring of adaptive tumor resistance to PD-1 checkpoint blockade M Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ... EUROPEAN JOURNAL OF CANCER 103, E4-E5, 2018 | | 2018 |
| Spatial re-distribution of natural killer cells targets drug resistance and anti-tumor response, ex-vivo M Smalley, BU Shanthappa, H Gertje, M Lawson, M Biswas, ... Cancer Research 78 (13_Supplement), 4064-4064, 2018 | | 2018 |
| Predicting unreported clinical trial efficacy using an ex-vivo tumor platform: Pembrolizumab+pt+5-FU vs. extreme in recurrent head and neck squamous cell … M Smalley, S Thiyagarajan, B Majumder, NP Basak, A Basu, ... Journal of Clinical Oncology 36 (15_suppl), e18042-e18042, 2018 | | 2018 |
Baraneedharan UlaganathanFounder, Rident Biosciences在 ridentbio.com 的电子邮件经过验证
